Nascent Biotech, Inc. Announces the Addition of Dr. Ralph Zipper to Advisory Board

VERO BEACH, FL / ACCESSWIRE / April 7, 2016 / Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC: NBIO), announced today the addition of Dr. Ralph Zipper, MD, FACOG, FPMRS to its Advisory Board. Dr. Zipper currently is a practicing physician and COO of Biofuse Medical Technologies, Inc.

“Dr. Zipper’s vast experience as an innovator in the specialty of Gynecology and an operator of various successful medical startup companies in Senior Management positions will help position Nascent Biotech for future development and corporate clinical direction,” said Nascent CEO, Sean Carrick.

Mr. Carrick has known Dr. Zipper for approximately twenty years and encouraged Dr. Zipper to join Nascent Biotech’s already impressive group of medical professionals currently on its Advisory Board.

“I recognize the significance of Nascent’s primary asset, Pritumumab, to potentially benefit multiple cancers and am honored to be contributing to Nascent’s pathway to success,” said Dr. Zipper.

About Nascent Biotech, Inc.:

Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.

Safe Harbor:

Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc.’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10K, filed on May 2, 2015 and subsequent future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact Information:

Nascent Biotech, Inc.
Sean Carrick
President | CEO
772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com

SOURCE: Nascent Biotech, Inc.

ReleaseID: 438576